PROFILAKTIKA TOShNOTY I RVOTY PRI PROVEDENII TsITOSTATIChESKOY TERAPII U VZROSLYKh


Citar

Texto integral

Resumo

Тошнота и рвота при проведении цитостатической терапии воспринимаются пациентами как наиболее тягостное осложнение лечения. Основными препаратами для профилактики и терапии острой тошноты и рвоты являются антагонисты рецепторов серотонина третьего типа (5-HT3-рецепторов): гранисетрон, трописетрон, ондансетрон, доласетрон, палоносетрон. Дексаметазон назначают одновременно с антагонистами 5-HT3-рецепторов, т. к. он потенцирует их действие. Food and Drug Administration США одобрена новая трансдермальная форма гранисетрона (Sancuso), эффективная при проведении многодневной химиотерапии. Антиэметический препарат апрепитант (селективный блокатор NK1-рецепторов) рекомендован для профилактики тошноты и рвоты при высоко эметогенной химиотерапии и применении режима доксорубицин + циклофосфамид.

Sobre autores

I Koroleva

M Kopp

Bibliografia

  1. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999;17:2971-94.
  2. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.
  3. Roila F, Basurto C, Bosnjak S, et al. Randomized, double-blind, dose-finding study of dexamethasone in prrowEventing acute emesis induced by anthracyclines, carboplatin or cyclophosphamide. J Clin Oncol 2004;22:725-9.
  4. Steven M, Grunberg, Paul J. et al. Control of Chemotherapy-Induced Emesis The New England journal of medicine 1993;329:1790-6
  5. Kaiser R, Sezer O, Papies A, et al. Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes J Clin Oncol 2002;20(12):2805-2811.
  6. Verna A, McDaniel RW, Nausea D. Vomiting, and retching: complex problems in palliative care. Cancer J Clin 2001;51:232-48.
  7. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 1996;52:639-48.
  8. Blower PR. A pharmacologic profile of oral granisetron. Eur J Cancer 1990;26(1):8-11.
  9. Lindley C, Blower P. Oral serotonin type 3 receptor antagonist for prevention of chemotherapy-induced emesis. Am J Health Sust Pharm 2000;15:1685-97.
  10. Van Wijngaarden I, Tulp MT, Soudijn W. The concept of selectivity in 5HT receptor research. Eur J Pharmacol 1990;138:301-12.
  11. Gebauer A, Merger M, Kilbinger H. Modulation by 5-HT3 receptor antagonist: correlation with anti-emetic response. Naunyn Schmiedebergs Arch Pharmacol 1993;347:137-40.
  12. Nelson Dr, Thomas DR. [3H]-BRL 43694 (granisetron), a specific ligand for 5-HT3 binding sites in rat brain cortical membranes. Biochem Pharmacol 1989;38:1693-95.
  13. Perez PR. Comparasion of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetigenic chemotherapy: doble-blinde, randomized, parallel study. J Clin Oncol 1989;16:754-60.
  14. Bishop JF, Matthews JP, Wolf MM, et al. A randomised trial of dexamethasone, lorazepam and prochlorperazine for emesis in patients receiving chemotherapy. Eur J Cancer 1992;28:47-50.
  15. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-8.
  16. Zaglama NE, Rosenblum SL, Sartiano GP, et al. Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy. Oncol 1986;43:27-32.
  17. Klygis LM. Dexamethasone-induced perineal irritation in head injury. Am J Emerg Med 1992;10:268.
  18. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. PrrowEvention of chemotherapy and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 1998;9:811-9.
  19. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. PrrowEvention of chemotherapy and radiotherapy-induced emesis: results of the 2004 Perugia Consensus Conference. Ann Oncol 2006;17:20-8.
  20. Cocquyt V, Van Belle S, Reinhardt RR, et al. L-758, 298, a prodrug for selective neurokinin-1 antagonist, L-754, 030, compared to ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001;37:835-42.
  21. Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapyinduced nausea and vomiting. Support Care Cancer 2001;9:350-54.
  22. Campos D, Periera JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by oral neurokinin-1 antagonist, MK-869, in combinatio with granisetron and dexametasone or with dexametasone alone. J Clin Oncol 2001;19(6):1759-67.
  23. Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prrowEvention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-300.
  24. Kirchner V, Aapro M, Terry J, et al. A double - blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nause and vomiting associated with chemotherapy. Eur J Cancer 1997;33(10):1605-10.
  25. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8.
  26. de Witt R, Herrstedt J, Rapoport B, et al. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III trials. Eur J Cancer 2004;40:403-10.
  27. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK1 antagonist aprepitant for the prrowEvention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo-controlled trials. Eur J Cancer 2005;41:1278-85.
  28. Scmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexametasone, for antiemetic efficacy in hight-dose cisplatin trestment. Ann Oncol 2006 17(6);1000-6.
  29. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006;24:2932-47.
  30. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prrowEvention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30.
  31. Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prrowEvention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55.
  32. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000;342:1554-9.
  33. Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prrowEvention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosteron with ondansetron. Ann Oncol 2003;14:1570-7.
  34. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prrowEvention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3-receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-82.
  35. Passik SD, Loehrer PJ, Navari RJ, et al. A phase I trial of olanzapine (Zyprexa) for theprrow Evention of delayed emesis in cancer patients receiving chemotherapy: A Hoosier Oncology Group study. Proc ASCO 2002;21:374.
  36. Granisetron transdermal system: A new option to help prevent chemotherapy-induced nausea and vomiting. Clin J Oncol Nursing 2009;13(6):711-4.
  37. Morrow GR, Lindke J, Black PM, et al. Predicting development of anticipatory emesis in cancer patients: prospective examination of eight characteristics. J Pain Symptom Manage 1991;6:215-23.
  38. Montgomery GH, Bovbierg DH. Expectations of chemotherapy-related nausea: emotional and experiential predictors. Ann Behav Med 2003;25:48-54.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2010

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies